Desang diabetes magazine diabetes news






The US Food and Drug

Administration (FDA) has approved

AstraZeneca's Xigduo XR, a oncedaily tablet that merges the recently

approved drug dapagliflozin with

metformin. Dapagliflozin, a product

of AstraZeneca and Bristol-Myers

Squibb, was approved by the FDA in

January 2014. It works by blocking

the absorption of excess glucose

by the kidneys, so sugar is released

through urine. Metformin, believed to

be the most widely used medication

to treat diabetes, particularly Type

2 diabetes, works by suppressing

glucose production by the liver.

Xigudo XR is already approved to

treat T2 diabetes in Australia, and a

similar version just called Xigduo has

been available in Europe since earlier

this year (2014). Gaining access to

the US market will be a shot in the

arm for AstraZeneca.


  1. Page 0001
  2. Page 0002
  3. Page 0003
  4. Desang diabetes magazine diabetes news
  5. Desang diabetes magazine diabetes news Type 2 testing
  6. Desang diabetes magazine diabetes diet
  7. Dexcom continuous blood glucose monitoring
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Bayer Contour Link USB blood test meter for Medtronic insulin pump
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Making Carbs Count leeks
  19. Accu-Chek Combo insulin pump
  20. Desang diabetes kitbags

Related Issues